PT  - JOURNAL ARTICLE
AU  - Poorni M. Manohar
AU  - Nancy E. Davidson
TI  - Updates in endocrine therapy for metastatic breast cancer
AID  - 10.20892/j.issn.2095-3941.2021.0255
DP  - 2022 Feb 01
TA  - Cancer Biology & Medicine
PG  - 202--212
VI  - 19
IP  - 2
4099  - http://www.cancerbiomed.org/content/19/2/202.short
4100  - http://www.cancerbiomed.org/content/19/2/202.full
SO  - Cancer Biol Med2022 Feb 01; 19
AB  - Endocrine therapy (ET) remains the mainstay of treatment for steroid hormone receptor-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC). Tumor resistance to hormone therapy has led to the development of novel endocrine drug combinations, transforming the landscape of MBC management. The options for ET are expanding, with promising agents in the pipeline. Although MBC remains incurable, many patients can enjoy years of survival with good quality of life by cycling through the many available agents. With the plethora of available agents and rapid approvals, clinicians look to evidence-based guidelines to assist in treatment selection to maximize patient well-being. In this review, we provide a contemporary review of the advances in ET and a suggested algorithm to guide clinicians in daily management of patients with hormone receptor-positive, HER2-negative MBC. We will discuss landmark trials and highlight their impact in reshaping treatment approaches. Finally, we will provide a glimpse into advances on the horizon and the promise they bring to improve outcomes in patients with advanced breast cancer.